Impact of molecular residual disease post allografting in myelofibrosis patients.
Bone Marrow Transplant
; 52(11): 1526-1529, 2017 Nov.
Article
en En
| MEDLINE
| ID: mdl-28714945
ABSTRACT
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F (n=101), thrombopoietin receptor gene (MPL) (n=4) or calreticulin (CALR) (n=31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI) 50-70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI 18-34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%, P<0.001) and 70% vs 10%, P<0.001, respectively) irrespectively of the underlying mutation. In a multivariate analysis, high-risk diseases status (hazard ratio (HR) 2.5; 95% CI 1.18-5.25, P=0.016) and detectable MRD at day 180 (HR 8.36, 95% CI 2.76-25.30, P<0.001) were significant factors for a higher risk of relapse.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasia Residual
/
Calreticulina
/
Janus Quinasa 2
/
Receptores de Trombopoyetina
/
Mielofibrosis Primaria
/
Patología Molecular
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
/
Middle aged
Idioma:
En
Revista:
Bone Marrow Transplant
Asunto de la revista:
TRANSPLANTE
Año:
2017
Tipo del documento:
Article
País de afiliación:
Alemania
Pais de publicación:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM